Trials / Completed
CompletedNCT06166914
Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment
Evaluation of 5-fluorouracil and Low Molecular Weight Heparin Intraoperative Infusion in Preventing Proliferative Vitreoretinopathy in High Risk Pediatric Rhegmatogenous Retinal Detachment
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Alexandria University · Academic / Other
- Sex
- All
- Age
- 0 Years – 14 Years
- Healthy volunteers
- Not accepted
Summary
EVALUATION OF 5-FLOUROURACIL AND LOW MOLECULAR WEIGHT HEPARIN INTRAOPERATIVE INFUSION IN PREVENTING PROLIFERATIVE VITREORETINOPATHY IN HIGH RISK PEDIATRIC RHEGMATOGENOUS RETINAL DETACHMENT
Detailed description
After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group A received intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml), group B received infusion of normal saline. Primary outcome was occurrence of recurrent PRRD within 12 weeks, secondary outcomes were occurrence of PVR, best corrected visual acuity (BCVA), number and timing of secondary procedures within 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml) | After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group A received intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml). |
| DRUG | Placebo | After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group B received infusion of normal saline. |
Timeline
- Start date
- 2021-10-21
- Primary completion
- 2022-10-21
- Completion
- 2023-05-21
- First posted
- 2023-12-12
- Last updated
- 2023-12-19
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06166914. Inclusion in this directory is not an endorsement.